CALCULATE YOUR SIP RETURNS

USFDA Grants Orphan Drug Designation to Zydus Lifesciences’ Usnoflast

Written by: Team Angel OneUpdated on: Jan 23, 2025, 2:29 PM IST
The US FDA has granted Orphan Drug Designation to Zydus Lifesciences’ Usnoflast, an experimental ALS treatment currently in clinical trials.
USFDA Grants Orphan Drug Designation to Zydus Lifesciences’ Usnoflast
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

The US Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) to Zydus Lifesciences’ Usnoflast, an oral NLRP3 inhibitor, for treating amyotrophic lateral sclerosis (ALS). ALS is a rare neurodegenerative condition that affects motor neurons in the brain and spinal cord.

Clinical Trials and Plans

Zydus conducted a Phase 2(a) randomised, double-blind, placebo-controlled clinical trial for Usnoflast with 24 ALS patients across seven sites in India. The results of this study are expected to be presented at a medical conference and published in a journal. Following this, the US FDA has approved the initiation of a Phase 2(b) clinical trial for ALS patients.

Incentives with Orphan Drug Designation

Drugs receiving the ODD status benefit from several development incentives, such as tax credits for clinical testing, exemptions from certain user fees, and eligibility for 7 years of marketing exclusivity once approved by the USFDA.

About Amyotrophic Lateral Sclerosis

ALS is a progressive and fatal disease that leads to muscle weakness, loss of voluntary movement, and eventual paralysis. Patients often lose their lives due to respiratory failure within two to five years of diagnosis. 

Usnoflast’s Broader Applications

Usnoflast has also been studied for other medical conditions, including Parkinson’s disease, inflammatory bowel disease (IBD), and multiple sclerosis (MS). Previously, the USFDA granted the drug ODD for treating Cryopyrin Associated Periodic Syndrome (CAPS), an autoinflammatory disease.

About Zydus Life Sciences 

Zydus Lifesciences is a pharmaceutical company based in Ahmedabad, India. It focuses on developing treatments for unmet medical needs, including rare diseases. The company employs over 27,000 individuals globally and is involved in producing healthcare therapies.

Shares of Zydus Lifesciences Ltd, as of 11:46 AM, January 23, are trading at ₹987.25, up by 0.89% today, though it has declined by 14.07% over the past 6 months while gaining 35.40% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing

Published on: Jan 23, 2025, 2:29 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 2.5 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 2.5 Cr+ happy customers